Bafna Pharmaceuticals Limited has informed the Exchange that the Members at the 30th Annual General Meeting of the Company held on September 19, 2025 had inter-alia approved (i) Appointment of Mr. Navin Kumar as Independent Director of the Company and (ii) Re-appointment of Mr. Palamadai Krishnan Sundaresan and Mrs. Ravichandran Chitra as Independent Directors of the Company
BAFNAPH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
At the 30th Annual General Meeting held on September 19, 2025, shareholders of Bafna Pharmaceuticals approved the appointment of Mr. Navin Kumar as a new Independent Director. They also approved the re-appointment of two existing Independent Directors, Mr. Palamadai Krishnan Sundaresan and Mrs. Ravichandran Chitra. These are standard corporate governance resolutions passed at the AGM. The company has not disclosed any other major business updates in this filing.
This is a routine AGM outcome with no material impact expected on the stock price or shareholders' interests. The continuity of independent directors supports ongoing board stability and governance oversight.